By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that its board of directors has authorized a $100 million stock repurchase program.
The latest buyback is the firm's third $100 million share repurchase program.
Registering provides access to this and other free content.
Already have an account?Login Now.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.